logo
ResearchBunny Logo
Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects

Medicine and Health

Harnessing Biomaterials for Safeguarding Chimeric Antigen Receptor T Cell Therapy: An Artful Expedition in Mitigating Adverse Effects

Z. Chen, Y. Hu, et al.

Discover how researchers Zhaozhao Chen, Yu Hu, and Heng Mei are tackling the challenges of CAR-T cell therapy, such as cytokine release syndrome and neurotoxicity. This innovative review unveils the potential of biomaterials to enhance safety and effectiveness, paving the way for a new era in cancer treatment.

00:00
00:00
Playback language: English
Abstract
Chimeric antigen receptor T (CAR-T) cell therapy demonstrates remarkable efficacy in cancer treatment but faces significant challenges due to adverse effects like cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and on-target off-tumor toxicities (OTOT). This review explores the use of biomaterials to mitigate these side effects. It delves into the mechanisms of CRS, ICANS, and OTOT, and presents innovative strategies using biomaterials to enhance the safety and efficacy of CAR-T cell therapy, transcending conventional treatment paradigms.
Publisher
Pharmaceutics
Published On
Jan 22, 2024
Authors
Zhaozhao Chen, Yu Hu, Heng Mei
Tags
CAR-T cell therapy
biomaterials
cytokine release syndrome
neurotoxicity
cancer treatment
therapy efficacy
on-target off-tumor toxicities

Related Publications

Explore these studies to deepen your understanding of the subject.

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects
Medicine and Health

Mathematical modeling insights into improving CAR T cell therapy for solid tumors with bystander effects

E. Kara, T. L. Jackson, et al.

Single-cell T-cell receptor repertoire profiling in dogs
Veterinary Science

Single-cell T-cell receptor repertoire profiling in dogs

M. H. Hoang, Z. L. Skidmore, et al.

Neutralizing IFNγ Improves Safety without Compromising Efficacy of CAR-T Cell Therapy in B-cell Malignancies
Medicine and Health

Neutralizing IFNγ Improves Safety without Compromising Efficacy of CAR-T Cell Therapy in B-cell Malignancies

S. Manni, F. D. Bufalo, et al.

A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma
Medicine and Health

A type I interferon footprint in pre-operative biopsies is an independent biomarker that in combination with CD8+ T cell quantification can improve the prediction of response to neoadjuvant treatment of rectal adenocarcinoma

A. Rezapour, D. Rydbeck, et al.

Listen, Learn & Level Up
Over 10,000 hours of research content in 25+ fields, available in 12+ languages.
No more digging through PDFs, just hit play and absorb the world's latest research in your language, on your time.
listen to research audio papers with researchbunny